The frequency of KRAS and BRAF mutations in intrahepatic cholangiocarcinomas and their correlation with clinical outcome
| Autor: | Robert A. Anders, Rebecca M. Dodson, Justin Poling, Suresh K. Nayar, Ming Tseh Lin, James R. Eshleman, Omar Hyder, Scott P. Robertson, Timothy M. Pawlik, Katie Beierl |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Oncology
Male Proto-Oncogene Proteins B-raf medicine.medical_specialty endocrine system diseases Viral Oncogene medicine.disease_cause Article Pathology and Forensic Medicine Cholangiocarcinoma Proto-Oncogene Proteins p21(ras) Internal medicine Proto-Oncogene Proteins Medicine Humans Survival rate Lymph node neoplasms Intrahepatic Cholangiocarcinoma Aged Neoplasm Staging Mutation business.industry Liver Neoplasms Wild type Middle Aged Prognosis digestive system diseases Survival Rate medicine.anatomical_structure Cancer research ras Proteins Female KRAS business Carcinogenesis |
| Zdroj: | Human pathology. 44(12) |
| ISSN: | 1532-8392 |
| Popis: | The incidence of intrahepatic cholangiocarcinoma is increasing worldwide. The prognosis of intrahepatic cholangiocarcinoma is poor, and a better understanding of intrahepatic cholangiocarcinoma tumor biology is needed to more accurately predict clinical outcome and to suggest potential targets for more effective therapies. v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) and BRAF are frequently mutated oncogenes that promote carcinogenesis in a variety of tumor types. In this study, we analyze a large set of intrahepatic cholangiocarcinoma tumors (n = 54) for mutations in these genes and compare the clinical outcomes of wild type versus KRAS and BRAF mutant cases. Of 54 cases, 7.4% were mutant for KRAS, 7.4% were mutant for BRAF, and these were mutually exclusive. These mutant cases were associated with a higher tumor stage at time of resection and a greater likelihood of lymph node involvement. These cases were also associated with a worse long-term overall survival. Therefore, testing for KRAS and BRAF mutations could be a valuable adjunct in improving both prognosis and outcome stratification among patients with intrahepatic cholangiocarcinoma. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect